DNAPrint Genomics, Inc.: DNAPrint Genomics and SeraCare's Genomics Collaborative Combine to Improve Outcome for Ovarian Cancer Treatment
14th Nov 2005, 14:22 GMT
SARASOTA, FL and OCEANSIDE, CA (MARKET WIRE) DNAPrint(TM) genomics, Inc. (OTC BB: DNAG) and the Cambridge, Mass.-based Genomics Collaborative Division of SeraCare Life Sciences, Inc., today announced that they have begun collaboration on a project designed to improve treatment for patients with ovarian cancer.
DNAPrint Genomics, Inc.: DNAPrint Genomics and SeraCare's Genomics Collaborative Combine to Improve Outcome for Ovarian Cancer Treatment related news:
- DNAPrint and SeraCare collaborate on ovarian cancer — Pharmaceutical Business Review Online
- DNAPrint genomics, Inc.: DNAPrint genomics to Acquire Ellipsis Biotherapeutics — Market Wire - Mergers and Acquisitions
- DNAPrint genomics, Inc.: DNAPrint genomics to Present at Investor Conference Sponsored by the Wall Street Analyst Forum — Market Wire - Pharmaceuticals and Biotech
- DNAPrint Genomics, Inc.: DNAPrint genomics CEO Richard Gabriel Featured in Interview in Wall Street Transcript's Biotechnology Issue — Market Wire - Pharmaceuticals and Biotech
- Ovarian cancer has an ally, ginkgo biloba — The Cancer Blog
- DNAPrint makes deal with Toronto drug firm — Latest news from Tampa Bay Business Journal
- Celera Genomics presents latest cancer-fighting research — Latest news from Washington Business Journal
- Lung cancer, newly identified protein may one day help improve treatment — Medical News Today RSS/XML Feed
- Ovarian cancer patients' receptivity to therapy can be determined by genes — The Cancer Blog
- Researchers Discover Molecular Differences between Low-, High-Grade Ovarian Cancers — Science Blog -
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech